Literature DB >> 10854549

Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer.

T Fujimura1, Y Yonemura, H Nakagawara, H Kitagawa, S Fushida, G Nishimura, I Miyazaki, K Shibata.   

Abstract

Treatment for peritonitis carcinomatosa in gastrointestinal cancer remains to be established though it is one of the commonest causes of cancer death. Subtotal peritonectomy (SP) with chemohyperthermic peritoneal perfusion (CHPP) was developed for the new therapeutic strategy for peritoneal dissemination in gastrointestinal cancer in our department. SP includes resection of stomach, colon, small bowel, spleen, gall bladder, and parietal peritoneum. CHPP was carried out by heated saline containing 25 mg/l cisplatin, 10 mg/l mitomycin C, and 20 mg/l etoposide. Intraperitoneal temperature was maintained at 42 degrees C for 60 min. Fifteen gastric cancer and three colon cancer patients with severe peritoneal dissemination underwent these procedures. The averages of operating time, intraoperative bleeding volume, and total perioperative transfused blood volume were 9 h, 4400 ml, and 5600 ml, respectively. The patients estimated as complete resection and residual disease by histopathological study numbered 11 and 7. There was no treatment-related deaths though bleeding occurred in 5 patients; perforation in 2 patients; and abscesses in 2 patients. The 1-year survival rate (1ysr) and the 2-year survival rate (2-ysr) of all the patients were 57% and 21%, respectively. The 1-ysr and the 2-ysr of the patients who underwent complete resection were 67% and 40% significantly greater than the 43% and 0% of the patients who had residual tumors (p=0.02). The combination therapy of SP and CHPP is feasible in spite of its morbidity and has great possibilities in complete resection of peritoneal dissemination and prolongation of patient's survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854549     DOI: 10.3892/or.7.4.809

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

1.  A 26-year-old female with metastatic primary gastrointestinal malignancy presenting as menorrhagia.

Authors:  Maliha Khan; Ravinder Pal Bhatti; Sarbajit Mukherjee; Alaa M Ali; Alan D Gilman; Aibek E Mirrakhimov; Nkemakolam Iroegbu
Journal:  J Gastrointest Oncol       Date:  2015-04

Review 2.  Intra-operative hyperthermic intraperitoneal chemotherapy for prevention and treatment of peritoneal metastases from gastric cancer: a narrative review.

Authors:  Zhong-He Ji; Ying Zhang; Yan Li
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer.

Authors:  Feihu Bai; Jie Liang; Jun Wang; Yongquan Shi; Kedong Zhang; Shuhui Liang; Liu Hong; Huihong Zhai; Yuanyuan Lu; Yu Han; Fang Yin; Kaichun Wu; Daiming Fan
Journal:  J Mol Med (Berl)       Date:  2006-10-17       Impact factor: 4.599

Review 4.  Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced gastric cancer.

Authors:  Zhouqiao Wu; Ziyu Li; Jiafu Ji
Journal:  Transl Gastroenterol Hepatol       Date:  2016-08-12

5.  Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.

Authors:  Qing-Guo Fu; Fan-Dong Meng; Xiao-Dong Shen; Ren-Xuan Guo
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.

Authors:  Takuji Mori; Yoshiyuki Fujiwara; Masahiko Yano; Shigeyuki Tamura; Takushi Yasuda; Shuji Takiguchi; Morito Monden
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

7.  Factors influencing outcome after surgery for stage IV colorectal cancer.

Authors:  Masayuki Hotokezaka; Sei-ichiro Jimi; Hideki Hidaka; Takuto Ikeda; Shuichiro Uchiyama; Shinya Nakashima; Kazuyo Tsuchiya; Kazuo Chijiiwa
Journal:  Surg Today       Date:  2008-08-28       Impact factor: 2.549

8.  Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Sumit Kapoor; Adel Bassily-Marcus; Rafael Alba Yunen; Parissa Tabrizian; Sabrine Semoin; Joseph Blankush; Daniel Labow; John Oropello; Anthony Manasia; Roopa Kohli-Seth
Journal:  World J Crit Care Med       Date:  2017-05-04

9.  Cytoreductive onco-surgery with combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy: Perioperative challenges.

Authors:  Rohini Dattatri; Rakesh Garg; Mukur Dipi Ray
Journal:  Saudi J Anaesth       Date:  2019 Apr-Jun

10.  Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study.

Authors:  Maneesh Kumarsing Beeharry; Zheng-Lun Zhu; Wen-Tao Liu; Xue-Xin Yao; Min Yan; Zheng-Gang Zhu
Journal:  BMC Cancer       Date:  2019-09-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.